Evaluating Stevanato Group’s primary container portfolio for LNP-based mRNA delivery
As lipid nanoparticle (LNP)-based drugs evolve, drug developers must navigate the complexities involved in keeping them both active and stable, requiring reliable and tested containers for their delivery.
Explore the findings of recent research by Stevanato Group and researchers at the University of Padua in Italy to learn more about evaluating prefilled syringe use for LNPs.
Download the whitepaper for insights on:
- Rapidly evolving LNP-based therapies and their anticipated container needs
- Understanding the gap in container-drug interaction data
- Prefilled syringe compatibility: results from Stevanato Group’s syringe solutions testing
- Container solutions for keeping LNPs both stable and active
- Identifying reliable and tested containers for delivery to de-risk LNP strategies
To download the white paper,
please complete the form.
You agree Citeline and Stevanato Group may contact you directly about industry news, products, services and events that may be of interest to you subject to the privacy policies of Citeline and Stevanato Group.
Inspire. Connect. Innovate.
